Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Japanese Early-stage Clinical Trial of Ultra-high Dose Methylcobalamin for Amyotrophic Lateral Sclerosis: a Pivotal Phase 3 Randomized Controlled Study

NCT03548311 is registered in ClinicalTrials.gov with Eisai Co., Ltd. as lead sponsor.

NCT NCT03548311
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03548311 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Japanese Early-stage Clinical Trial of Ultra-high Dose Methylcobalamin for Amyotrophic Lateral Sclerosis: a Pivotal Phase 3 Randomized Controlled Study
Lead sponsor
Eisai Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
November 1, 2017
Completion date
February 18, 2025
Enrollment
130 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis